20+ yrs in Top 100 US Law Firms devising IP strategies for biopharma companies, conducting licensing & IP due diligence; developing worldwide IP portfolios for publicly listed companies in Taiwan and USA
Prosyla Group P.C. Principal & COO, Global Life Science Practice Group
20+ years of experience in Taiwan's capital markets through work in the underwriting departments of Yuanta Securities, IBT Securities, and E.SUN Securities; handled initial public offerings (IPOs) for companies in the information services, electronics, and biotechnology sectors
Professor Emeritus, Harvard Medical School; Academician in Taiwan; Founder of multiple biotech ventures, including Fuji ImmunoPharmaceuticals, Shionogi BioResearch, Caxton Life Science Partners, TaiMed Biologics, Synta Pharmaceuticals and Sequential Medicine
Over 25 years of experience in drug development; specializes in the operational responsibility for all aspects of R&D from benchtop through Phase 3 clinical trials, having managed more than 40 clinical trials under multiple INDs and CTAs across a variety of therapeutic indications in numerous countries
Over 25 years of experience managing biotechnology companies from the start-up phase through periods of rapid growth into complex publicly traded entities; experienced in venture building through three successful IPOs
Over 20 of antibody discovery and development experiences in pharma and biotech including Merck, JnJ, Mersana Therapeutics and IGM Biosciences. Led project teams to bring numerous therapeutic antibodies from concept to the clinic
Over 20 years in the clinical trials industry; senior management level strategic planning & execution, experienced in clinical research & development, with extensive networks and industry knowledge
